Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

244 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Invasive pneumococcal disease in children aged younger than 5 years in India: a surveillance study.
Manoharan A, Manchanda V, Balasubramanian S, Lalwani S, Modak M, Bai S, Vijayan A, Shet A, Nagaraj S, Karande S, Nataraj G, Yewale VN, Joshi SA, Iyer RN, Santosham M, Kahn GD, Knoll MD; Alliance for Surveillance of Invasive Pneumococci (ASIP) Study Group. Manoharan A, et al. Among authors: lalwani s. Lancet Infect Dis. 2017 Mar;17(3):305-312. doi: 10.1016/S1473-3099(16)30466-2. Epub 2016 Dec 10. Lancet Infect Dis. 2017. PMID: 27956163
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine vaccines in India.
Amdekar YK, Lalwani SK, Bavdekar A, Balasubramanian S, Chhatwal J, Bhat SR, Verghese VP, Tansey SP, Gadgil D, Jiang Q, Pride M, Emini EA, Gruber WC, Scott DA. Amdekar YK, et al. Among authors: lalwani sk. Pediatr Infect Dis J. 2013 May;32(5):509-16. doi: 10.1097/INF.0b013e31827b478d. Pediatr Infect Dis J. 2013. PMID: 23190777 Clinical Trial.
Immunogenicity and safety of early vaccination with two doses of a combined measles-mumps-rubella-varicella vaccine in healthy Indian children from 9 months of age: a phase III, randomised, non-inferiority trial.
Lalwani S, Chatterjee S, Balasubramanian S, Bavdekar A, Mehta S, Datta S, Povey M, Henry O. Lalwani S, et al. BMJ Open. 2015 Sep 11;5(9):e007202. doi: 10.1136/bmjopen-2014-007202. BMJ Open. 2015. PMID: 26362659 Free PMC article. Clinical Trial.
Immunogenicity, safety, and reactogenicity of the 10-valent pneumococcal non-typeable Hemophilus influenzae protein D conjugate vaccine (PHiD-CV) when co-administered with the DTPw-HBV/Hib vaccine in Indian infants: a single-blind, randomized, controlled study.
Lalwani S, Chatterjee S, Chhatwal J, Verghese VP, Mehta S, Shafi F, Borys D, Moreira M, Schuerman L. Lalwani S, et al. Hum Vaccin Immunother. 2012 May;8(5):612-22. doi: 10.4161/hv.19287. Epub 2012 May 1. Hum Vaccin Immunother. 2012. PMID: 22634448 Clinical Trial.
Randomized, open-label study of the impact of age on booster responses to the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine in children in India.
Lalwani S, Chatterjee S, Chhatwal J, Simon A, Ravula S, Francois N, Mehta S, Strezova A, Borys D. Lalwani S, et al. Clin Vaccine Immunol. 2014 Sep;21(9):1292-300. doi: 10.1128/CVI.00068-14. Epub 2014 Jul 9. Clin Vaccine Immunol. 2014. PMID: 25008901 Free PMC article. Clinical Trial.
Efficacy, Immunogenicity, and Safety of a 9-Valent Human Papillomavirus Vaccine: Subgroup Analysis of Participants From Asian Countries.
Garland SM, Pitisuttithum P, Ngan HYS, Cho CH, Lee CY, Chen CA, Yang YC, Chu TY, Twu NF, Samakoses R, Takeuchi Y, Cheung TH, Kim SC, Huang LM, Kim BG, Kim YT, Kim KH, Song YS, Lalwani S, Kang JH, Sakamoto M, Ryu HS, Bhatla N, Yoshikawa H, Ellison MC, Han SR, Moeller E, Murata S, Ritter M, Sawata M, Shields C, Walia A, Perez G, Luxembourg A. Garland SM, et al. Among authors: lalwani s. J Infect Dis. 2018 Jun 5;218(1):95-108. doi: 10.1093/infdis/jiy133. J Infect Dis. 2018. PMID: 29767739 Free PMC article. Clinical Trial.
244 results